Latest News and Press Releases

iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August Gosselies, Belgium – August 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies,...

iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...

iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...

iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director   Two new appointments follow oversubscribed $75...

iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director   Two new appointments follow oversubscribed $75...

iTeos Therapeutics Completes $75 Million Series B Financing   Oversubscribed financing round led by new U.S. investor MPM Capital  Proceeds to support accelerated development of innovative...

iTeos Therapeutics Completes $75 Million Series B Financing   Oversubscribed financing round led by new U.S. investor MPM Capital  Proceeds to support accelerated development of innovative...

iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Gosselies, Belgium - April 12, 2018 - iTeos Therapeutics SA, a biotechnology...

iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference Two Phase 1 trials to start in 2018 for A2A...

iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference Two Phase 1 trials to start in 2018 for A2A...